{
    "nctId": "NCT01357772",
    "briefTitle": "Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up",
    "officialTitle": "Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Number of invasive breast cancer events and DCIS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women of age \u2265 18 and \\< 75 years\n2. Women operated on for lobular (LIN 2 and 3) or ER positive or unknown ductal DCIS, i.e DIN 1-3, but DIN 1a excluded) intraepithelial neoplasia in the 5 years (60 months) prior the inclusion in the study. Both incident (diagnosis \\< 12 months) and prevalent cases diagnosis \u226512, and \\< 60 months) will be included, including recurrent cases\n3. ECOG Performance status \u2264 1\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Any type of malignancy, with the exclusion of non-melanoma skin cancer\n2. Proliferative disorders of the endometrium such as atypical hyperplasia, endometriosis, unresected polyps, symptomatic myoma\n3. Liver, kidney and heart function impairment grade \u2265 2 (CTCAE criteria v.3.0)\n4. Any type of retinal disorders, severe cataract and glaucoma\n5. Presence of significant risk factors for venous events, including immobilization after trauma within the last 3 months for longer than 2 weeks, deep venous thrombophlebitis or other significant venous thrombotic event,VTE (pulmonary embolism, stroke, etc.)\n6. Use of tamoxifen, raloxifene or other selective estrogen receptor modulator (SERMs)\n7. Use of anastrozole and other aromatase inhibitors (AI) in the last 12 months for \u2265 6 months\n8. Dicoumarol anticoagulant therapy in progress\n9. Active infections\n10. Severe psychiatric disorders or inability to comply to the protocol procedures\n11. Geographic inaccessibility or difficulties in ensuring adequate compliance\n12. Women who are pregnant or breastfeeding\n13. Any other factor which, at the discretion of the investigator, may controindicate the use of tamoxifen",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}